In CRC, several potential targets have been studied over the past 20 years (Figure 2), including epidermal growth factor receptor (EGFR) inhibition [10] as well as suppression of the Ras–Raf–MEK–ERK pathway, which is responsible for cell growth, proliferation and survival [11,12]. This evidence concerns the gene EGFR and colorectal carcinoma.